PEPTIDE CORTEXThe library
← The library

Mazdutide

region-specificMetabolic/Weight
Evidence grade
BRegion-specific approval (not US FDA)
Cardiovascular · 0–5 · separate axis
3
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight
MechanismDual GLP-1 and glucagon receptor agonist; the glucagon arm adds energy expenditure to appetite suppression
EffectsBeat semaglutide 1 mg on both weight and glycaemic control in a head-to-head Phase 3 trial
DosingNo human dose established.
Bottom lineApproved in some jurisdictions; not FDA-reviewed, so US access is via unregulated channels.
Protocols · as published1 sourced
Clinical trialGLORY-1 (Ji, NEJM 2025)
RouteSubcutaneous injection
FrequencyOnce weekly, 48 weeks
Starting2 mg weekly for 4 weeks
Escalation4 mg arm: 4 mg for 44 weeks. 6 mg arm: 4 mg for 4 weeks, then 6 mg for 40 weeks.
Target4 mg or 6 mg weekly. 48-week weight change -11.00% and -14.01% vs +0.30% placebo.
Maximum6 mg weekly (maximum studied here)

Approved in China (Innovent); the Chinese label was not retrieved. Not FDA-approved.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Approved in China; not FDA-approved. GI effects typical of the incretin class.

Delays gastric emptying, which affects absorption of oral medicines; hypoglycaemia risk with insulin or sulfonylureas.

CV 3 of 5 — Strong metabolic and weight effects imply cardiometabolic benefit, but no dedicated cardiovascular outcomes trial has reported.